IMMX · Immix Biopharma, Inc.
$13.16
-0.03 (-0.23%)
At close · Aug 20
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern. The continuation of the Company as a going concern is dependent upon its ability to obtain continued financial support from its stockholders, necessary equity financing to continue operations and the attainment of profitable operations.”View the 10-Q filed Aug 7, 2026
Market Cap
$943.60M
Shares
71.54M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$20M
0%
FY2024
Net Income
-$29.4M
-36%
FY2025
Operating Margin
-149.78%
-36.4pp
FY2025
Diluted EPS
-$0.89
-17.1%
FY2025
Operating Cash Flow
-$23.93M
-64%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | $20M | $20M | $20M | — | — | — | |
| $21.62M | $16.26M | $11.29M | $8.74M | $4.2M | $126.53K | $248.15K | |
| $20.19M | $13.7M | $11.38M | $7.41M | $4.02M | $1.23M | $205.7K | |
| $41.82M | $29.96M | $22.67M | $16.14M | $8.22M | $1.35M | $453.85K | |
| -$41.82M | -$29.96M | -$22.67M | -$16.14M | -$8.22M | -$1.35M | -$453.85K | |
| — | -149.78% | -113.37% | -80.71% | — | — | — | |
| — | — | — | — | $497 | $179.85K | $101.98K | |
| $1.93M | $555.53K | $1.02M | $572.01K | — | — | — | |
| $1.93M | $555.53K | $1.02M | $572.01K | -$497 | -$23.03M | -$676.46K | |
| -$39.88M | -$29.4M | -$21.66M | -$15.57M | -$8.22M | -$24.38M | -$1.13M | |
| — | $37.72K | $41.04K | $26.42K | $10.27K | $6013 | $17.55K | |
| -$39.88M | -$29.4M | -$21.61M | -$15.43M | -$8.23M | -$24.38M | -$1.15M | |
| — | -147% | -108.07% | -77.13% | — | — | — | |
| — | — | -$84.99K | -$169.47K | — | — | — | |
| — | — | -$21.75M | -$15.38M | -$8.27M | -$24.39M | -$1.08M | |
| USD/shares | — | -$0.89 | -$0.76 | -$0.89 | -$0.59 | -$6.64 | — |
| USD/shares | — | -$0.89 | -$0.76 | -$0.89 | -$0.59 | — | — |
| shares | — | 32.97M | 28.29M | 17.34M | 13.89M | 3.67M | 3.38M |
| shares | — | 32.97M | 28.29M | 17.34M | 13.89M | 3.67M | 3.38M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 6.96×
EV/EBIT
—
Peer median 21.30×
P/E (TTM)
—
Peer median 13.94×
Peer medians compare against the 298 similar-size Biotechnology companies (of 546 listed).